Cover image not available

Costing statement : Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasa

National Institute for Health and Clinical Excellence

Publication Data

Title Costing statement : Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasa
Alternative Title Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib
Author National Institute for Health and Clinical Excellence
Publisher National Institute for Health and Clinical Excellence
Publication date 2012
Publication location London
Language English

Descriptive Notes

"Technology appraisal implementation tools."

Topics

Chronic myeloid leukemia :: Chemotherapy :: England :: Cost effectiveness
Protein-tyrosine kinase :: Inhibitors
Imatinib

Catalogue Data

OBNB ID GBB586180
ISBN 10 n/a
ISBN 13 n/a
Type BibliographicResource, Book
Dewey Classification 616.99419061

ISBD

P1053 1 online resource (6 unnumbered pages).

Buy a copy

OBNB doesn't sell books, but you may be able to find a copy at one of these websites:

Costing statement : Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasa by National Institute for Health and Clinical Excellence. Published by National Institute for Health and Clinical Excellence in 2012. Publication and catalogue information, links to buy online and reader comments.